De Angelis R. Sant M. Coleman M.P. et al.

Cancer survival in europe 1999-2007 by country and age: Results of eurocare--5-a population-based study.

Lancet Oncol. 15: 23-34Siegel R.L. Miller K.D. Jemal A.

Cancer statistics, 2016.

CA Cancer J Clin. 66: 7-30Ross-Innes C.S. Becq J. Warren A. et al.

Whole-genome sequencing provides new insights into the clonal architecture of barrett's esophagus and esophageal adenocarcinoma.

Nat Genet. 47: 1038-1046Stachler M.D. Taylor-Weiner A. Peng S. et al.

Paired exome analysis of barrett's esophagus and adenocarcinoma.

Nat Genet. 47: 1047-1055Hao J.J. Lin D.C. Dinh H.Q. et al.

Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma.

Nat Genet. 48: 1500-1507

Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers.

Therap Adv Gastroenterol. 13: 1-20Hu Y. Bandla S. Godfrey T.E. et al.

Her2 amplification, overexpression and score criteria in esophageal adenocarcinoma.

Mod Pathol. 24: 899-907Bartley A.N. Washington M.K. Ventura C.B. et al.

Her2 testing and clinical decision making in gastroesophageal adenocarcinoma: Guideline from the college of american pathologists, american society for clinical pathology, and american society of clinical oncology.

Arch Pathol Lab Med. 140: 1345-1363Westphalen C.B. Krebs M.G. Le Tourneau C. et al.

Genomic context of ntrk1/2/3 fusion-positive tumours from a large real-world population.

NPJ Precis Oncol. 5: 69Gatalica Z. Xiu J. Swensen J. et al.

Molecular characterization of cancers with ntrk gene fusions.

Mod Pathol. 32: 147-153Brown L.M. Devesa S.S. Chow W.H.

Incidence of adenocarcinoma of the esophagus among white americans by sex, stage, and age.

J Natl Cancer Inst. 100: 1184-1187Devesa S.S. Fraumeni Jr., J.F.

The rising incidence of gastric cardia cancer.

J Natl Cancer Inst. 91: 747-749Prasad G.A. Bansal A. Sharma P. et al.

Predictors of progression in barrett's esophagus: Current knowledge and future directions.

Am J Gastroenterol. 105: 1490-1502

Esophageal cancer.

N Engl J Med. 349: 2241-2252Lagergren J. Bergstrom R. Lindgren A. et al.

Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma.

N Engl J Med. 340: 825-831Picardo S.L. Maher S.G. O'Sullivan J.N. et al.

Barrett's to oesophageal cancer sequence: a model of inflammatory-driven upper gastrointestinal cancer.

Dig Surg. 29: 251-260Poehlmann A. Kuester D. Malfertheiner P. et al.

Inflammation and barrett's carcinogenesis.

Pathol Res Pract. 208: 269-280Shaheen N.J. Falk G.W. Iyer P.G. et al.

Acg clinical guideline: diagnosis and management of barrett's esophagus.

Am J Gastroenterol. 111 (): 30-50Weston A.P. Sharma P. Mathur S. et al.

Risk stratification of barrett's esophagus: updated prospective multivariate analysis.

Am J Gastroenterol. 99: 1657-1666Smyth E.C. Lagergren J. Fitzgerald R.C. et al.

Oesophageal cancer.

Nat Rev Dis Primers. 3: 17048Romero Y. Cameron A.J. Locke 3rd, G.R. et al.

Familial aggregation of gastroesophageal reflux in patients with barrett's esophagus and esophageal adenocarcinoma.

Gastroenterology. 113: 1449-1456Chak A. Lee T. Kinnard M.F. et al.

Familial aggregation of barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in caucasian adults.

Gut. 51: 323-328Gharahkhani P. Fitzgerald R.C. Vaughan T.L. et al.

Genome-wide association studies in oesophageal adenocarcinoma and barrett's oesophagus: a large-scale meta-analysis.

Lancet Oncol. 17: 1363-1373Arnold M. Ferlay J. van Berge Henegouwen M.I. et al.

Global burden of oesophageal and gastric cancer by histology and subsite in 2018.

Gut. 69: 1564-1571Domper Arnal M.J. Ferrandez Arenas A. Lanas Arbeloa A.

Esophageal cancer: risk factors, screening and endoscopic treatment in western and eastern countries.

World J Gastroenterol. 21: 7933-7943Torre L.A. Bray F. Siegel R.L. et al.

Global cancer statistics, 2012.

CA Cancer J Clin. 65: 87-108Ferlay J. Soerjomataram I. Dikshit R. et al.

Cancer incidence and mortality worldwide: sources, methods and major patterns in globocan 2012.

Int J Cancer. 136: E359-E386Engel L.S. Chow W.H. Vaughan T.L. et al.

Population attributable risks of esophageal and gastric cancers.

J Natl Cancer Inst. 95: 1404-1413Ellis A. Risk J.M. Maruthappu T. et al.

Tylosis with oesophageal cancer: diagnosis, management and molecular mechanisms.

Orphanet J Rare Dis. 10: 126

Carcinoma of the esophagus and tylosis. A lethal genetic combination.

Cancer. 72: 17-19

Fanconi anemia: Young patients at high risk for squamous cell carcinoma.

Mol Cell Pediatr. 1: 9Cunniff C. Bassetti J.A. Ellis N.A.

Bloom's syndrome: clinical spectrum, molecular pathogenesis, and cancer predisposition.

Mol Syndromol. 8: 4-23Secrier M. Li X. de Silva N. et al.

Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.

Nat Genet. 48: 1131-1141Nones K. Waddell N. Wayte N. et al.

Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis.

Nat Commun. 5: 5224Dulak A.M. Stojanov P. Peng S. et al.

Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity.

Nat Genet. 45: 478-486Alexandrov L.B. Nik-Zainal S. Wedge D.C. et al.

Signatures of mutational processes in human cancer.

Nature. 500: 415-421Farris 3rd, A.B. Demicco E.G. Le L.P. et al.

Clinicopathologic and molecular profiles of microsatellite unstable barrett esophagus-associated adenocarcinoma.

Am J Surg Pathol. 35: 647-655Weaver J.M.J. Ross-Innes C.S. Shannon N. et al.

Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis.

Nat Genet. 46: 837-843

Cancer Genome Atlas Research N, Analysis Working Group: Asan U, Agency BCC et al. Integrated genomic characterization of oesophageal carcinoma.

Nature. 541: 169-175Bang Y.J. Van Cutsem E. Feyereislova A. et al.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of her2-positive advanced gastric or gastro-oesophageal junction cancer (toga): A phase 3, open-label, randomised controlled trial.

Lancet. 376: 687-697Stephens P.J. Greenman C.D. Fu B. et al.

Massive genomic rearrangement acquired in a single catastrophic event during cancer development.

Cell. 144: 27-40Zack T.I. Schumacher S.E. Carter S.L. et al.

Pan-cancer patterns of somatic copy number alteration.

Nat Genet. 45: 1134-1140Stratton M.R. Campbell P.J. Futreal P.A.

The cancer genome.

Nature. 458: 719-724Newell F. Patel K. Gartside M. et al.

Complex structural rearrangements are present in high-grade dysplastic barrett's oesophagus samples.

BMC Med Genomics. 12: 31Kim Y. Hammerman P.S. Kim J. et al.

Integrative and comparative genomic analysis of lung squamous cell carcinomas in east asian patients.

J Clin Oncol. 32: 121-128Cancer Genome Atlas Research N.

Comprehensive genomic characterization of squamous cell lung cancers.

Nature. 489: 519-525

Comprehensive genomic characterization of head and neck squamous cell carcinomas.

Nature. 517: 576-582Liu X. Zhang M. Ying S. et al.

Genetic alterations in esophageal tissues from squamous dysplasia to carcinoma.

Gastroenterology. 153: 166-177Moody S. Senkin S. Islam S.M.A. et al.

Mutational signatures in esophageal squamous cell carcinoma from eight countries with varying incidence.

Nat Genet. 53: 1553-1563Cheng C. Zhou Y. Li H. et al.

Whole-genome sequencing reveals diverse models of structural variations in esophageal squamous cell carcinoma.

Am J Hum Genet. 98: 256-274Matejcic M. Gunter M.J. Ferrari P.

Alcohol metabolism and oesophageal cancer: A systematic review of the evidence.

Carcinogenesis. 38: 859-872Lin D.C. Dinh H.Q. Xie J.J. et al.

Identification of distinct mutational patterns and new driver genes in oesophageal squamous cell carcinomas and adenocarcinomas.

Gut. 67: 1769-1779Cancer Genome Atlas Research N.

Comprehensive molecular characterization of gastric adenocarcinoma.

Nature. 513: 202-209Galipeau P.C. Prevo L.J. Sanchez C.A. et al.

Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (barrett's) tissue.

J Natl Cancer Inst. 91: 2087-2095Li X. Galipeau P.C. Sanchez C.A. et al.

Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in barrett's esophagus neoplastic progression.

Cancer Prev Res (Phila). 1: 413-423Reid B.J. Barrett M.T. Galipeau P.C. et al.

Barrett's esophagus: Ordering the events that lead to cancer.

Eur J Cancer Prev. 5: 57-65Wong D.J. Paulson T.G. Prevo L.J. et al.

P16(ink4a) lesions are common, early abnormalities that undergo clonal expansion in barrett's metaplastic epithelium.

Cancer Res. 61: 8284-8289Yousef F. Cardwell C. Cantwell M.M. et al.

The incidence of esophageal cancer and high-grade dysplasia in barrett's esophagus: A systematic review and meta-analysis.

Am J Epidemiol. 168: 237-249Desai T.K. Krishnan K. Samala N. et al.

The incidence of oesophageal adenocarcinoma in non-dysplastic barrett's oesophagus: A meta-analysis.

Gut. 61: 970-976Hvid-Jensen F. Pedersen L. Drewes A.M. et al.

Incidence of adenocarcinoma among patients with barrett's esophagus.

N Engl J Med. 365: 1375-1383Bhat S. Coleman H.G. Yousef F. et al.

Risk of malignant progression in barrett's esophagus patients: Results from a large population-based study.

J Natl Cancer Inst. 103: 1049-1057Sikkema M. de Jonge P.J. Steyerberg E.W. et al.

Risk of esophageal adenocarcinoma and mortality in patients with barrett's esophagus: A systematic review and meta-analysis.

Clin Gastroenterol Hepatol. 8 (): 235-244Sharma P. Falk G.W. Weston A.P. et al.

Dysplasia and cancer in a large multicenter cohort of patients with barrett's esophagus.

Clin Gastroenterol Hepatol. 4: 566-572Dulai G.S. Shekelle P.G. Jensen D.M. et al.

Dysplasia and risk of further neoplastic progression in a regional veterans administration barrett's cohort.

Am J Gastroenterol. 100: 775-783Weston A.P. Sharma P. Topalovski M. et al.

Long-term follow-up of barrett's high-grade dysplasia.

Am J Gastroenterol. 95: 1888-1893Rastogi A. Puli S. El-Serag H.B. et al.

Incidence of esophageal adenocarcinoma in patients with barrett's esophagus and high-grade dysplasia: A meta-analysis.

Gastrointest Endosc. 67: 394-398Schnell T.G. Sontag S.J. Chejfec G. et al.

Long-term nonsurgical management of barrett's esophagus with high-grade dysplasia.

Gastroenterology. 120: 1607-1619Galipeau P.C. Li X. Blount P.L. et al.

Nsaids modulate cdkn2a, tp53, and DNA content risk for progression to esophageal adenocarcinoma.

PLoS Med. 4: e67Rygiel A.M. Milano F. Ten Kate F.J. et al.

Gains and amplifications of c-myc, egfr, and 20.Q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of barrett's esophagus.

Cancer Epidemiol Biomarkers Prev. 17: 1380-1385Schulmann K. Sterian A. Berki A. et al.

Inactivation of p16, runx3, and hpp1 occurs early in barrett's-associated neoplastic progression and predicts progression risk.

Oncogene. 24: 4138-4148Reid B.J. Prevo L.J. Galipeau P.C. et al.

Predictors of progression in barrett's esophagus ii: Baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.

Am J Gastroenterol. 96: 2839-2848Stachler M.D. Camarda N.D. Deitrick C. et al.

Detection of mutations in barrett's esophagus before progression to high-grade dysplasia or adenocarcinoma.

Gastroenterology. 155: 156-167Maley C.C. Galipeau P.C. Finley J.C. et al.

Genetic clonal diversity predicts progression to esophageal adenocarcinoma.

Nat Genet. 38: 468-473Revilla-Nuin B. Parrilla P. Lozano J.J. et al.

Predictive value of micrornas in the progression of barrett esophagus to adenocarcinoma in a long-term follow-up study.

Ann Surg. 257: 886-893Redston M. Noffsinger A. Kim A. et al.

Abnormal tp53 predicts risk of progression in patients with barrett’s esophagus regardless of a diagnosis of dysplasia.

Gastroenterology. 162: 468-481Kastelein F. Spaander M.C. Biermann K. et al.

Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with barrett's esophagus.

Gastroenterology. 141 (): 2000-2008Murray L. Sedo A. Scott M. et al.

Tp53 and progression from barrett's metaplasia to oesophageal adenocarcinoma in a uk population cohort.

Gut. 55: 1390-1397Li M. Anastassiades C.P. Joshi B. et al.

Affinity peptide for targeted detection of dysplasia in barrett's esophagus.

Gastroenterology. 139: 1472-1480Bird-Lieberman E.L. Neves A.A. Lao-Sirieix P. et al.

Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in barrett's esophagus.

Nat Med. 18: 315-321Krishnadath K.K. van Blankenstein M. Tilanus H.W.

Prognostic value of p53 in barrett's oesophagus.

Eur J Gastroenterol Hepatol. 7: 81-84Weston A.P. Banerjee S.K. Sharma P. et al.

P53 protein overexpression in low grade dysplasia (lgd) in barrett's esophagus: Immunohistochemical marker predictive of progression.

Am J Gastroenterol. 96: 1355-1362Kadri S.R. Lao-Sirieix P. O'Donovan M. et al.

Acceptability and accuracy of a non-endoscopic screening test for barrett's oesophagus in primary care: Cohort study.

BMJ. 341: c4372Elliott D.R.F. Walker A.W. O'Donovan M. et al.

A non-endoscopic device to sample the oesophageal microbiota: A case-control study.

Lancet Gastroenterol Hepatol. 2: 32-42Munch N.S. Fang H.Y. Ingermann J. et al.

High-fat diet accelerates carcinogenesis in a mouse model of barrett's esophagus via interleukin 8 and alterations to the gut microbiome.

Gastroenterology. 157: 492-506 e492